Seer IncSEER
SEER
About: Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
Employees: 134
0
Funds holding %
of 7,334 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
4.51% less ownership
Funds ownership: 53.92% [Q4 2024] → 49.41% (-4.51%) [Q1 2025]
6% less funds holding
Funds holding: 71 [Q4 2024] → 67 (-4) [Q1 2025]
32% less capital invested
Capital invested by funds: $68.4M [Q4 2024] → $46.6M (-$21.8M) [Q1 2025]
45% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 29
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
67% less call options, than puts
Call options by funds: $1K | Put options by funds: $3K
Research analyst outlook
We haven’t received any recent analyst ratings for SEER.
Financial journalist opinion
Based on 6 articles about SEER published over the past 30 days
Neutral
Seeking Alpha
4 days ago
Seer, Inc. (SEER) Q2 2025 Earnings Call Transcript
Seer, Inc. (NASDAQ:SEER ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants David R. Horn - President,Treasurer & CFO Kelly Gura - Corporate Participant Omid C.
Positive
The Motley Fool
4 days ago
Seer (SEER) Q2 Revenue Jumps 32%
Seer (SEER -2.83%), a life sciences technology firm specializing in advanced proteomics, released its second quarter results for fiscal 2025 on August 6, 2025. Seer reported GAAP revenue of $4.1 million, topping consensus estimates of $3.75 million by $0.35 million and marking a 32% increase from the prior-year period.
Neutral
Zacks Investment Research
4 days ago
Seer, Inc. (SEER) Reports Q2 Loss, Beats Revenue Estimates
Seer, Inc. (SEER) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.35 per share a year ago.
Neutral
GlobeNewsWire
4 days ago
Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
Revenue grew 32% year-over-year, driven by increased product sales and service revenue Launched new high-throughput Proteograph ® ONE assay and SP200 automation instrument REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2025.
Neutral
GlobeNewsWire
1 week ago
Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference
REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA.
Neutral
GlobeNewsWire
2 weeks ago
Seer to Report Second Quarter 2025 Financial Results on August 6, 2025
REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 6, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Positive
Zacks Investment Research
2 months ago
What Makes Seer, Inc. (SEER) a Strong Momentum Stock: Buy Now?
Does Seer, Inc. (SEER) have what it takes to be a top stock pick for momentum investors? Let's find out.
Neutral
GlobeNewsWire
2 months ago
Seer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
First-of-its-kind study will use Seer's next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics
Neutral
GlobeNewsWire
2 months ago
Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency
REDWOOD CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the launch of its new Proteograph® Product Suite, featuring the Proteograph ONE Assay and SP200 Automation Instrument—its most advanced solution yet for scalable, high-resolution, mass spec-based proteomics.
Neutral
Seeking Alpha
2 months ago
Seer, Inc. (SEER) Q1 2025 Earnings Call Transcript
Seer, Inc. (NASDAQ:SEER ) Q1 2025 Results Conference Call May 13, 2025 4:30 PM ET Company Participants Kelly Gura - Investor Relations Omid Farokhzad - Chief Executive Officer and Chair of the Board David Horn - Chief Financial Officer and President Conference Call Participants Rachel Vatnsdal - JPMorgan Operator Good day, and thank you for standing by. Welcome to Seer first quarter 2025 earnings conference call.
Charts implemented using Lightweight Charts™